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Abstract
Introduction
Interleukin (IL)-18 is involved in regulation of lipid and glucose metabolism. Mice lacking
whole-body IL-18 signalling are prone to develop weight gain and insulin resistance, a phe-
notype which is associated with impaired fat oxidation and ectopic skeletal muscle lipid
deposition. IL-18 mRNA is expressed in human skeletal muscle but a role for IL-18 in muscle
has not been identified. Patients with HIV-infection and lipodystrophy (LD) are characterized
by lipid and glucose disturbances and increased levels of circulating IL-18. We hypothesized
that skeletal muscle IL-18 and IL-18 receptor (R) expression would be altered in patients
with HIV-lipodystrophy.
Design and methods
Twenty-three HIV-infected patients with LD and 15 age-matched healthy controls were
included in a cross-sectional study. Biopsies from the vastus lateralis muscle were obtained
and IL-18 and IL-18R mRNA expression were measured by real-time PCR and sphingoli-
pids (ceramides, sphingosine, sphingosine-1-Phosphate, sphinganine) were measured by
HPLC. Insulin resistance was assessed by HOMA and the insulin response during an
OGTT.
Results
Patients with HIV-LD had a 60% and 54% lower level of muscular IL-18 and IL-18R mRNA
expression, respectively, compared to age-matched healthy controls. Patients with HIV-LD
had a trend towards increased levels of ceramide (18.3±4.7 versus 14.8±3.0,p = 0.06) and
sphingosine (0.41±0.13 versus 0.32±0.07, and lower level of sphinganine (p = 0.06). Low
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levels of muscle IL-18 mRNA correlated to high levels of ceramides (r = -0.31, p = 0.038)
and sphingosine-1P (r = -0.29, p = 0.046) in skeletal muscle, whereas such a correlation
was not found in healthy controls. Low expression of IL-18 mRNA in skeletal muscle corre-
lated to elevated concentration of circulating triglycerides (Rp = -0.73, p<0.0001). Neither
muscle expression of IL-18 mRNA or ceramide correlated to parameters of insulin
resistance.
Conclusion
IL-18 (mRNA) in skeletal muscle appears to be involved in the regulation of intramuscular
lipid metabolism and hypertriglyceridemia.
Introduction
The cytokine interleukin (IL)-18 is a member of the IL-1 family and has been identified as a
cofactor that, together with IL-12, stimulates production of interferon gamma [1]. IL-18 is
widely expressed in many mammalian cells/tissues including liver, adipose tissue and skeletal
muscle [2–4] [5]. IL-18 is best known for its role in inflammation, whereby pro-inflammatory
stimuli such as lipopolysaccharide, and tumor necrosis factor (TNF)-α leads to caspase-1
mediated cleavage of pro-IL-18 into mature IL-18. IL-18 is synthesized as an inactive precursor
molecule (Pro-IL-18) that lacks a signal peptide and requires cleavage into a mature, active
cytokine IL-18 that is then secreted from the cell [6].
IL-18 can then signal via a heterodimer of the transmembrane IL-18 receptors (α and β),
and via a toll like receptor signaling cascade ultimately leading to the activation of nuclear fac-
tor κB (NFκB) and subsequent regulation of gene transcription [7]. Additional signaling path-
ways of IL-18 also exist, including activation of phosphatidylinositol-3 kinase (PI3K)/Akt
[8,9], signal transducer and activator of transcription 3 (STAT 3) [10], mitogen-activated pro-
tein kinases (MAPK) [8,10], and c-Jun NH2-terminal kinase (JNK) [9,11] which are all impli-
cated in energy metabolism.
As IL-18 plays a role in inflammation it is not surprisingly that circulating IL-18 levels are
elevated in human obesity [12] and in patients with type 2 diabetes [13,14]. IL-18 is expressed
in adipose tissue [15,16] especially in visceral adipose tissue [17,18].
Paradoxically, IL-18 has also been found to be directly involved in the regulation of lipid
and glucose metabolism as mice lacking whole-body IL-18 signalling become obese and insu-
lin resistant, [19,20]. In a previous study, we demonstrated that IL-18 receptor deficient mice
display obesity, insulin resistance, impaired fat oxidation and ectopic lipid deposition in liver
and skeletal muscle [21]. Moreover, administration of IL-18 to whole muscle strips ex vivo
increased AMPK signaling and increases fat oxidation, and in vivo electroporation of IL-18
into skeletal muscle results in increased AMPK signaling and expression of mitochondrial
genes in skeletal muscle and concomitantly inhibits high fat diet-induced-weight gain, suggest-
ing that IL-18 is increasing skeletal muscle fat oxidation via AMPK and oppose ectopic lipid
accumulation [21]. Taken together, in the progression toward obesity, there is continual pro-
duction of IL-18 to oppose ectopic lipid accumulation [22]. However, the cellular origin of IL-
18 remains enigmatic, although it has been shown that IL-18 released from adipose tissue is
not produced by the adipocytes themselves [16,23]. Given that IL-18 is expressed in human
skeletal muscle and exerts its effect on lipid metabolism in skeletal muscle ex vivo and in vivo
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in rodents, it suggest that IL-18 is regulated in skeletal muscle and associated to lipid metabo-
lism. However, the role of IL-18 in skeletal muscle in humans have never been investigated.
A syndrome of lipodystrophy, characterised by subcutaneous fat loss, and a relative increase
in central fat accumulation, was previously seen in patients with HIV, when treated with a
combination of antiretroviral therapy, including thymidine-nucleoside analogues [24–26].
Lipodystrophy is mostly caused by antiretroviral induced adipose tissue dysfunction [27,28]
and is associated with impaired fat oxidation [29,30], ectopic lipid deposition in muscle and
liver [24,30–32], and mitochondrial dysfunction in skeletal muscle [33] leading to dyslipidemia
and insulin resistance [24,25]. Elevated circulating levels of IL-18 are observed in HIV-infected
patients and especially those with lipodystrophy [34,35]. The increase in circulating IL-18 is
associated to the fat redistribution and in part derived from subcutaneous adipose tissue
[36,37].
The ectopic accumulation of lipids in the skeletal muscle is closely linked with insulin resis-
tance [38]. In the recent years it is found that it is not the total amount of lipid but the lipid
intermediates causing insulin resistance. The lipid intermediates account for sphingolipids,
e.g. ceramides, sphingosine, sphingoanine, sphingosine-1-P, and diacylglycerol (DAG) [39].
Especially, ceramides [40] and DAG have been supposed to induce insulin resistance [38].
Besides antagonize insulin signalling recent data also shows that ceramides impair mitochon-
drial functions [41].
In this study, we included material from a cohort of HIV patients with lipodystrophy [42]
in order to obtain more information about the metabolic role of IL-18 in humans. Patients
with HIV-lipodystrophy share some of the same metabolic disturbances as mice lacking IL-18
signalling but paradoxically the systemic levels of IL-18 are increased in those patients. We
therefore aimed at determining whether muscle IL-18 mRNA and IL-18 receptor mRNA are
altered, either increased or decreased, in these patients. Given the strong link between cer-
amides and insulin resistance [38] and mitochondrial function [41], we further studied the
possible association of muscle IL-18 mRNA with ceramides and other sphingolipids.
Patients and methods
Patients and controls
A group of 23 HIV-infected men were recruited from the outpatient clinic of the Department
of Infectious Disease, Rigshospitalet in Copenhagen. These subjects have been included in a
former study and the inclusions of the subjects are described therein [42]. In short, LD was
defined clinically by physical examination of peripheral lipoatrophy (defined by the presence
of peripheral lipoatrophy with at least one moderate sign of fat loss in face, arms, buttocks, or
legs based on a physical examination by a single investigator (BL) using a validated question-
naire developed by Carr et al [43]). All patients were on a stable and effective nucleoside ana-
logue based antiretroviral therapy with no changes during the preceding 8 weeks.
Two groups of healthy controls were included: Fifteen age-matched HIV-negative healthy
men served as controls for RT-PCR data (Group 1). These subjects have also been included in
the before mentioned study [42]. But as muscle tissue for measurement of sphingolipids from
healthy controls in group 1 were available for only two healthy subjects, 17 new healthy age-
matched control subjects were included (Group 2). Demographic data were collected for each
patient: age, duration of HIV infection, duration and types of all antiretroviral therapy, weight,
height, CD4 count, HIV-RNA copies. Inclusion criteria: no signs of ongoing infections; fasting
glucose< 7 mmol/L and 120 min glucose after an OGTT< 11.1 mmol/L, no dyslipidemia (tri-
glycerides >1.7 mmol/L and/or HDL-cholesterol <0.9 mmol/L); suppressed viral load (<20
copies/mL). Exclusion criteria: Severe cardiovascular diseases; arthritis; severe neuropathy;
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hepatitis C; opportunistic infections that required hospitalisation within the last 6 weeks; dia-
betes (fasting glucose7 mmol/L or 2-hrs. glucose >11 mmol/L after an OGTT); concurrent
therapy with antidiabetic agents, anticoagulant or any hormones.
Written informed consent was obtained from all subjects according to the requirements
from the local ethical committee and the Helsinki Declaration II, and the approval from the
local ethical committee (KF 01269485): The Ethics Committee of Copenhagen and Frederiks-
berg) was obtained.
Biochemical measurements
Peripheral blood samples were obtained at 8 AM after an overnight fasting. Measurements of
total cholesterol (mmol/L), HDL-cholesterol (mmol/L), LDL-cholesterol (mmol/L), triglycer-
ides (mmol/L), plasma glucose (mmol/L) and insulin (pmol/L), were determined immediately
using routine methods.
CD4 cell counts were calculated by flowcytometry and HIV-RNA copies were measured by
the Amplicor HIV Monitor (Roche Molecular Systems, Branchburg, NJ) (lower limit of dec-
tection: 20 copies/ml).
Body composition analysis
Fat and fat-free tissue masses for whole body, trunk and extremities were measured using
dual-energy X-ray absorptiometry (DXA) scanner (Lunar Prodigy, GE Medical Systems Wis-
consin, USA, version 8.8) [43]. Whole-body and regional fat measurements (trunk and
extremities) were determined as previously described [44].
Maximal oxygen consumption (VO2max)
An incremental exercise to volitional fatigue was performed between 0800 h and 1000 h on a
cycle ergometer (Monark 839E, Monark Ltd, Varberg, Sweden). Maximal oxygen consump-
tion (VO2max) was measured with an indirect calorimetric system (Moxus modular VO2 sys-
tem, AEI Technologies, Pittsburgh, PA) using a 2-way non-rebreathing valve (Hans Rudolph,
Inc. Kansas City, Missouri) which recorded data every 15 seconds. Based on the pre-VO2max
test a protocol was designed in order to reach VO2max within 8–12 min of exercise start [45].
Exhaustion was defined by two of the following: respiratory exchange ratios >1.10, VO2
reached a plateau and/or rpm<60 in more than 10 sec.
Insulin sensitivity
Insulin resistance was assessed from several measurements: fasting plasma insulin, homeosta-
sis model (HOMA-IR) [46] and area under the curve (AUC) for the insulin concentration dur-
ing a 75-g oral glucose tolerance test (OGTT)
Muscle tissue biopsies
Muscle tissue biopsies were obtained after an overnight fast by use of the percutaneous biopsy
technique with suction from the quadriceps muscle under local anaesthesia with 2% lidocaine.
Muscle tissue was immediately frozen in liquid nitrogen and stored at –80˚C until analysed.
RNA extraction. RNA was extracted using Trizol™ (Life Technologies) according to man-
ufacturer’s protocol. In short, 1 ml of Trizol™ was added to 20–30 mg of muscle tissue and
homogenized using a Polytron (PT-MR2100, Kinematica) on setting 25–30 for 20–30 s and
placed on ice. All samples were added 100 μl of chloroform, shaken vigorously and incubated
for 5 min on ice. Samples were spun at 12000 g for 15 min at 4˚C, and the upper aqueous
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phase was placed in a fresh eppendorph tube. The same volume of isopropanol was added and
samples were placed at –20˚C for 1 hour followed by centrifugation at 12000 g for 15 min at
4˚C. The resulting RNA pellet was washed with 75% ethanol in DEPC-treated water and spun
at 6000 g for 10 min at 4˚C. The pellets were dissolved in DEPC-treated water.
Reverse transcription. One μg of total RNA was reverse transcribed in a 50-μl reaction
according to manufacturer’s protocol (Applied Biosystems, Taqman™ reverse transcription
reagents) with the use of random hexamer primers. The reactions were run in a Perkin Elmer
GeneAmp PCR system 9700 with conditions at 25˚C for 10 min, 48˚C for 30 min, and 95˚C
for 5 min.
Analysis of gene expression levels in muscle tissue. Samples were analyzed for IL-18 and
IL-18 receptor mRNA levels by real-time PCR using an ABI PRISM 7900 sequence detector
(PE Biosystems). The gene expression levels were normalized to the housekeeping gene
GAPDH (obtained from Applied Biosystems). Human IL-18 (Hs00155517_m1) and human
IL-18 receptor (Hs00187256_m1) primers and Taqman1 probe were obtained from Applied
Biosystems. All reactions were run in triplicates.
Data were quantitated and normalized using the standard curve method.
Sphingolipid analysis. The content of S1P, SA1P, sphingosine, sphinganine, and cer-
amide was determined as described previously in detail (Knapp et al. 2013). Briefly, lipids were
extracted from samples in the presence of internal standards (10 pmol of C17-sphingosine and
30 pmol of C17-S1P, Avanti Polar Lipids, Alabaster, AL). An aliquot of the lipid extract was
transferred to a fresh tube with pre-added 40 pmol of N-palmitoyl-D-erythro-sphingosine
(C17 base) (a kind gift of Dr Z. Szulc, Medical University of South Carolina) as an internal
standard, and then subjected to alkaline hydrolysis to deacylate ceramide to sphingosine. The
amount of S1P and SA1P was determined indirectly after dephosphorylation to sphingosine
and sphinganine, respectively, with the use of alkaline phosphatase (bovine intestinal mucosa,
Sigma). Free sphingosine and sphinganine, dephosphorylated sphingoid bases, and sphingo-
sine released from ceramide were then converted to their o-phthalaldehyde derivatives and
analyzed using a HPLC system (ProStar, Varian Inc., Palo Alto, CA) equipped with a fluores-
cence detector and C18 reversed-phase column (Varian Inc. OmniSpher 5, 4.6×150mm). The
isocratic eluent composition of acetonitrile (Merck, Darmstadt, Germany): water (9:1, v/v)
and a flow rate of 1 ml/min were used. Column temperature was maintained at 30˚C [47].
Statistical analysis
Statistical calculations were performed using SAS 9.1 (USA). Data are presented as means +/-
SD. P< 0.05 was considered significant in all analyses. Parameters between patients with
HIV-lipodystrophy and healthy controls were compared with a Mann-Whitney test. Pearson’s
correlations were used to examine the relationship between mRNA expression in muscle,
sphingolipid in muscle and markers of insulin sensitivity, as well as with anthropometric
parameters.
Results
Baseline characteristics
Demographic data, blood biochemistry and body composition appear in Table 1.
The healthy men and the patients with HIV-lipodysstrophy were age-matched. Two groups
of healthy men were included due to lack of muscle tissue. Group 1 served as controls for the
RT-PCR data. Group 2 served as controls for sphingolipid analysis.
IL-18 and IL-18 receptor expression and ceramides in muscles in HIV lipodystrophy
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Table 1. Baseline characteristics of patients and healthy controls.
Group 1 Group 2
Variab Healthy controls (n = 15) Patients with HIV-LD (n = 23) Healthy controls (n = 17) Patients with HIV-LD (n = 14)§
Age (years) 47.5 (6.1) 47.9 (9.5) 46.5 (6.0) 48.3 (9.7)
Duration of HIV infection (years) 15.6 (9.6) 13.9 (7.0)
Duration of antiretroviral therapy (years) 10.3 (4.3) 8.9 (3.8)
CD4+ cell (cells/μl) 558 (208) 550 (250)
LogHIV-RNA (copies/ml) 1.33 (0.12) 1.32 (0.11)
Antiretroviral use
Current Tymidine-NRTI use, No. (%) 11 (47.8) 7 (50.0)
Current PI use, No. (%) 13 (56.7) 8 (57.1)
Current NNRTI use, No. (%) 11 (47.8) 7 (50.0)
Physical activity parameters
VO2max (LO2/min) 2.5 (0.6) 2.3 (0.5) 3.4 (0.8) 2.4 (0.5)

Body composition
Body-mass index (kg/m2) 23.7 (1.9) 23.7 (2.9) 23.3 (2.1) 24.1 (3.0)
Weight (kg) 76.9 (7.4) 73.6 (11.2) 79.4 (9.0) 75.8 (11.1)
Waist (cm) 90 (5.7) 93.6 (6.4) 91.1 (7.9) 94.2 (7.2)
Waist-to.hip ratio 0.94 (0.03) 1.01 (0.04) 0.91 (0.05) 1.02 (0.04)
Fat mass (kg) 15.7 (4.4) 13.8 (5.3) 16.2 (6.4) 15.0 (5.3)
Trunk fat mass (kg) 8.9 (3.0) 9.8 (3.9) 9.1 (4.0) 10.9 (4.0)
Trunk fat percentage (%) 56.1(5.2) 71.2 (6.2)  55.3 (5.1) 72.5 (5.8)
Limb fat mass (kg) 6.2 (1.5) 3.5 (1.6) 6.6 (2.5) 3.6 (1.5)
Limb fat percentage (%) 40.2 (4.9) 25.1 (6.1)  41.5 (4.2) 24.0 (5.7)
Trunk-to-limb fat ratio 1.4 (0.29) 3.09 (1.17) 1.4 (0.25) 3.3 (1.3)
Lean mass (kg) 58.2 (5.2) 57.0 (6.8) 61.0 (5.4) 57.9 (6.2)
Metabolic parameters
Total-cholesterol (mmol/L) 4.63 (0.64) 5.5 (0.9) 4.81 (0.65) 5.8 (0.7)
HDL-C (mmol/L) 1.51 (0.32) 1.23 (0.52) 1.41 (0.32) 1.21 (0.36)
LDL-C (mmol/L) 3.3 (0.6) 3.7 (0.9) 3.14 (0.74) 3.94 (0.81)
Triglycerides (mmol/L) 0.76 (0.24) 2.55(1.43) 0.96 (0.26) 2.88 (1..34)
Glucose (mmol/L) 5.2 (0.3) 5.4 (0.6) 5.0 (0.1) 5.4 (0.7)
Insulin (pmol/L) 25 (8.9) 52 (25) 28.4 (9.9) 56.5 (28.2)
HOMA-IR 0.99 (0.37) 2.2 (1.4) 1.3 (0.14) 2.5 (1.5)
Glucose area under the curve (mmol/
Lmin)
670 (126) 826 (200) 654 (153) 779 (176)
Insulin area under the curve (pmol/Lmin) 23505 (10598) 52360 (31017) 18436 (10510) 45388 (37026)
Two groups of healthy men were included due to lack of muscle tissue. Group 1 served as controls for the RT-PCR data. Group 2 served as controls for the sphingolipid
analysis.
§ Fourteen patients with HIV-LD are a part of the 23 patients with HIV-LD in group 1.
Data are presented as mean (SD). PI, protease inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non- nucleoside reverse transcriptase inhibitor.
HOMA-IR, homeostatic model assessment for insulin resistance.
P< 0.05;
 P < 0.01;
P< 0.001,
P< 0.0001 by t-test comparing patients with HIV-LD and healthy controls within each cohort.
https://doi.org/10.1371/journal.pone.0186755.t001
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In group 1, patients were matched based on their VO2 max. In group 2 we also tried to
match HIV patients with their control based on physical activity, but at the end of the inclu-
sion the HIV patients had lower levels of VO2 max compared with controls (Table 1).
Patients with HIV-lipodystrophy were characterised by reduced total limb fat mass,
increased percentage of trunk fat mass, reduced percentage of limb fat mass and increased
trunk-to-limb fat mass, indicating fat redistribution, compared to healthy controls. No differ-
ences were found regarding BMI, total fat mass, trunk fat mass or lean body mass.
Fasting triglycerides and total-cholesterol levels were higher in patients with HIV-lipody-
strophy and so were fasting insulin, HOMA-IR and the insulin response during an OGTT
when compared to control subjects from both group 1 and 2, indicating insulin resistance in
patients with HIV-lipodystrophy (Table 1).
As previously demonstrated, plasma IL-18 was increased in patients with HIV-lipodystro-
phy compared to healthy controls (247 pg/ml (98) vs 199 pg/ml (102), p<0.05).
IL-18 and IL-18 receptor mRNA expression in skeletal muscle
IL-18 mRNA (Fig 1A) and IL-18 receptor mRNA (Fig 1B) expression were reduced by 60%
and 54%, respectively, in skeletal muscle in patients with HIV-lipodystrophy compared to
healthy controls. (IL-18 mRNA: p = 0.0005 IL-18 receptor mRNA: p = 0.018). In the healthy
control group, two subjects had very high levels of IL-18 mRNA. If these two subjects were
excluded, IL-18 mRNA expression was still significantly lower in patients with HIV-lipody-
strophy compared to healthy controls (p = 0.003) (data not shown).
Sphingolipid in skeletal muscle
The sphingolipids ceramide (Fig 2A) and sphingosine (Fig 2B) content in muscle tended to be
elevated in patients with HIV-lipodystrophy compared to healthy controls (P = 0.06).
Fig 1. Patients with HIV-lipodystrophy have reduced levels of IL-18 mRNA and IL-18 receptor mRNA in skeletal muscle. (A) mRNA expression of
IL-18 in skeletal muscle. In the healthy control group 2 subjects had very high levels of IL-18 mRNA levels. Even if those two subjects were deleted the
difference between healthy controls and patients with HIV-Lipodystrophy were still high significant p = 0.003). (B) mRNA expression of IL-18 receptor
in skeletal muscle. The levels of IL-18 mRNA and IL-18 receptor mRNA were calculated with GAPDH as a housekeeping gene. In the dot plots data for
each subjects are given and the line represent means and SD.  P<0.05 and P<0.001 for healthy vs HIV-lipodystrophy patients.
https://doi.org/10.1371/journal.pone.0186755.g001
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The sphinganine content in muscle tended to be lower in patients with HIV-lipodystrophy
compared to healthy controls (Fig 2D, p = 0.06)
Relationship between IL-18 mRNA and sphingolipid in skeletal muscle and
circulating lipids
In patients with HIV-lipodystrophy, low expression of IL-18 mRNA in skeletal muscle corre-
lated to high levels of ceramides (Rp = -0.56; p = 0.038) (Fig 3A) and high levels of sphingo-
sine-1P (IL-18 mRNA Rp = -0.54, p = 0.046) (Fig 3C). The same trend was observed for
sphingosine (Rp = -0.43, p = 0.12) (Fig 3E). In healthy subjects, IL-18 mRNA in skeletal muscle
did not correlate to muscle sphingolipids (Fig 3B, 3D and 3F), although the correlation for
sphingosine-1P only included 8 samples and a possible correlation may be lost due to low n-
value.
Reduced expression of IL-18 mRNA in skeletal muscle was associated with increased levels
of circulating triglycerides in all subjects pooled together (Rp = -0.73, p<0.0001) (Fig 3G). The
same observation was found for IL-18R mRNA expression in skeletal muscle (Rp = -0.56,
p = 0.0004, data not shown). When patients with HIV-lipodystrophy and healthy subjects
were analysed individually, the same correlation between IL-18 mRNA and triglycerides
Fig 2. The sphingolipids ceramide and sphingosine tended to be increased in vastus lateralis muscle from patients with HIV-lipodystrophy. In the
dot plots data for each subjects are given and the line represent means and SD.
https://doi.org/10.1371/journal.pone.0186755.g002
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Fig 3. The correlation relationship between muscle IL-18 mRNA and muscle sphingolipid content, circulating
triglycerides and HDL-cholesterol in patients with HIV-lipodystrophy (to the right) and in healthy controls (to
the left). IL-18 mRNA in muscle is negatively correlated to ceramide (A) and sphingosine-1P (C) content in muscle in
patients with HIV-Lipodystrophy, but not in healthy controls (B, D, F). Il-18 mRNA in muscle is negatively correlated
to triglycerides in patients with HIV-Lipodystrophy and in healthy controls (G), and positively correlated to
IL-18 and IL-18 receptor expression and ceramides in muscles in HIV lipodystrophy
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remained (HIV-LD Rp = -0.51, p = 0.02; Healthy subjects Rp = -0.69, p = 0.014). Reduced
expression of IL-18 mRNA and IL-18R mRNA in skeletal muscle was also associated with
reduced levels of HDL-cholesterol in all subjects together (for IL-18 mRNA: Rp = 0.39,
p = 0.01; for IL-18R mRNA: Rp = 0.48, p = 0.002) (Fig 3H) but not when the groups were ana-
lysed separately. No correlations were found between total-cholesterol or LDL-cholesterol and
IL-18 mRNA (data not shown).
As patients with HIV-lipodystrophy had a lower VO2 max than the healthy controls in
group 2 we examined if the increased levels of sphingolipids were related to low levels of VO2
max in patients with HIV-lipodystrophy. There was, however, no correlation between sphin-
golipids and VO2max/kg (ceramide Rp = 0.23, p = 0.42; Sphingosine-1P Rp = 0.20, p = 0.48;
sphingosine Rp = 0.37, p = 0.19).
In addition, no correlation was found between muscle IL-18 mRNA expression and fat dis-
tribution (BMI, fat mass, limb or trunk fat mass) in healthy controls or in patients with HIV-
lipodystrophy when analysed separately (data not shown).
No correlation was found between muscle IL-18 mRNA expression and glucose metabolism
(plasma insulin, HOMA, glucose and insulin response during an OGTT) in healthy controls
or in patients with HIV-lipodystrophy when analysed separately (data not shown).
Expression of mitochondrial genes and fatty acid transporters in skeletal
muscles and correlation to ceramide content in skeletal muscle
Patients with HIV-lipodystrophy displayed lower mRNA expressions of β-hydroxy acyl-CoA
dehydrogenase (β-HAD) (p = 0.004) (Fig 4A) and cytochrome c oxidase (p = 0.03) (Fig 4B)
compared to controls. No differences between groups were observed for citrate synthase, CPT-
1, and PGC-1 alpha (Fig 4C, 4D and 4E).
In patients with HIV-Lipodystrophy the content of ceramide in muscle correlated negative
to the levels of β-HAD mRNA expressions (R = -0.61; p = 0.02) (Fig 4F), but not to cytochrome
c oxidase (R = -0.10, p = 0.72) (Data not shown).
Discussion
The major finding of this study is that the expression of IL-18 mRNA and IL-18 receptor
mRNA is reduced in skeletal muscle in patients with HIV-lipodystrophy compared to healthy
age-matched men. Furthermore, low expression of muscle IL-18 mRNA correlates to high lev-
els of ceramides in skeletal muscle and to increased levels of circulating triglycerides and low
levels of HDL-cholesterol in patients with HIV-lipodystrophy.
IL-18 and IL-18 receptor in skeletal muscle
IL-18 is expressed in skeletal muscle [5] and high expression of IL-18 has been reported in
skeletal muscle in inflammatory diseases such as inflammatory myopathies [48] and COPD
[49]. Macrophages and dendritic cells are suggested to be the main producers of IL-18 [48].
Furthermore, it has been suggested that inflammation e.g. TNF-α trigger the IL-18 expression
in skeletal muscle [50].
In contrast to those studies, we found a reduced expression of IL-18 and IL-18 Receptor
mRNA in skeletal muscles in patients with HIV-lipodystrophy compared to healthy controls,
although circulating IL-18 was increased in those patients. Therefore, we conclude that IL-18
HDL-Cholesterol in patients with HIV-lipodystrophy. Regressions lines, correlations coefficient and significance levels
are given for healthy controls and patients with HIV-Lipodystrophy separately.
https://doi.org/10.1371/journal.pone.0186755.g003
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Fig 4. Patients with HIV-Lipodystrophy have reduced levels of HAD mRNA (A) and Cytochrome c mRNA (B) in skeletal muscle, but no
difference in citrate synthase mRNA (C), CPT-1 mRNA (D) and PGC-1 mRNA (E). HAD mRNA correlated negatively to the ceramide
content (F). The levels of genes were calculated with GAPDH as a housekeeping gene. In the dot plots data for each subjects are given and the
line represent means and SD.  P<0.05 and P<0.001 for healthy vs HIV-lipodystrophy patients. Regressions lines are given HIV-patients
separately.
https://doi.org/10.1371/journal.pone.0186755.g004
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signaling pathway is impaired in skeletal muscle in patients with HIV-lipodystrophy and that
the muscle cell is not a source of circulating IL-18. Instead, we suggest that in healthy humans
IL-18 is working in a local manner in skeletal muscle. It has previously been demonstrated that
IL-18 mRNA is induced e.g. by TNF without influence circulating IL-18 [50]. Furthermore,
several proteins (e.g. IL-8 and BDNF) are produced by skeletal muscle but not released into
the circulation, and those proteins work via autocrine or paracrine mechanisms, exerting their
effects on signalling pathways within the muscle itself [51].
The explanation for reduced IL-18 and IL-18 receptor expression in skeletal muscle is
intriguing as the underlying mechanisms for the IL-18 production and IL-18 receptor regula-
tion are still poorly understood. IL-18 production is tightly regulated, and achieved in a cas-
pase-1 dependent or in a caspase-1-independent way. The components for cleavage of
caspase-1, the inflammasome complexes, such as nucleotide-binding oligomerization domain
receptors 1 (NLRP)-1, NLRP-3 and NLRC-4, is present in adipose tissue [52], and in skeletal
muscle [53]. In adipose tissue, NLRP1 is an innate immune sensor that functions in the context
of metabolic stress to produce IL-18, preventing obesity and diet-induced metabolic dysfunc-
tion [22,23]. NLRP1 is also highly expressed in skeletal muscle in humans [54], but it is
unknown how NLRP1 is regulated in skeletal muscle and if NLRP-1 stimulates production of
IL-18 in skeletal muscle, in a similar way as in adipose tissue.
The reduced IL-18 and IL-18 receptor in skeletal muscle in patients with HIV-Lipodystro-
phy may also be link to IL-18 resistance. Obese subjects and person with type 2 diabetes dem-
onstrate impaired IL-18 responsiveness in leucocyte despite increased circulating levels of IL-
18 [55]. The IL-18 receptor is suggested to be the responsible molecular site for the observed
IL-18 resistance, as leucocyte from obese and type 2 diabetics demonstrated a reduced IL-18
receptor expression on leucocyte. However, no mechanism for reduced IL-18 receptor expres-
sion was found and the expression of IL-18 on the leucocyte was not measured. Netea and col-
leagues [55] explains IL-18 resistance as an immunological phenomenon; and hypothesize that
a similar resistance to the metabolic effect of IL-18 is also present [55]. It is possible that the
reduced IL-18 receptor expression in skeletal muscle found in the current study play a role in a
resistance to the metabolic effects of IL-18. This has been shown for IL-6. where skeletal mus-
cle in obesity-associated type 2 diabetes develops a resistance to IL-6 [56]. However, this
hypothesis has to be tested an in vitro study.
The role of IL-18 in lipid metabolism
In the last years, several animal studies have demonstrated that IL-18 play a role in metabo-
lism, which is independent of its inflammatory role. Mice lacking IL-18 or the IL-18 receptor
and therefore impaired IL-18 signalling become obese and display hyperinsulinemia, insulin
resistance and dyslipidemia [19–21]. We found an inverse correlation between IL-18 expres-
sion in skeletal muscle and systemic triglycerides and HDL-cholesterol in both healthy sub-
jects and in patients with HIV-lipodystrophy. Production of VLDL-TG is in part due to be
the increased flux of FFA to the liver in combination with insulin resistance associated
hyperinsulinemia [57,58] and this may be a way linking the role of IL-18 in skeletal muscle
to dyslipidemia.
In addition, IL-18 and IL-18 receptor deficient mice have an excess of intramyocellular lip-
ids (IMCL) which in part is explained by impaired beta-oxidation in muscle due to a defect in
one of major pathway that regulates fatty acid oxidation AMP-activated protein kinase
(AMPK) [21]. Treating myotubes or skeletal muscle strips with IL-18 activates AMPK and
increases fat oxidation. Furthermore, overexpression of IL-18 in mice leads to reduced fat
mass, increased activation of AMPK and increased mRNA abundance of β-hydroxyacyl-CoA-
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dehydrogenase (HAD), a key enzyme involved in mitochondrial function and hence increased
fat oxidation [21] -, implicating IL-18 in metabolic homeostasis.
Having found that IL-18 mRNA expression was lower in skeletal muscle in patients with
HIV-lipodystrophy, we investigated whether this was associated to an increased content of
IMCL, as observed in mice lacking the IL-18 signalling pathway [21]. It is known that patients
with HIV-lipodystrophy have increased level of IMCLs [24,30–32]. IMCLs are mainly com-
posed by triacylglycerol but also include lipid intermediates such as diacylglycerol, sphingoli-
pid, and phospholipid. Sphingolipids, including ceramide, sphingosine, sphingosine-1P and
sphinganine have never been measured in skeletal muscle from patients with HIV-lipodystro-
phy, but are altered in other metabolic state such as obesity and type 2 diabetes. [59–61]. We
found a trend towards increased contents of the sphingolipids ceramide and sphingosine, and
that the reduced levels of IL-18 mRNA in muscle correlated with increased contents of cer-
amides and sphingosine-1P in patients with HIV-lipodystrophy, but not in healthy controls,
demonstrating that skeletal muscle IL-18 and sphingolipids are linked. As this study is a cross-
sectional study it is not possible to describe the causal relationship. Ceramide has been demon-
strated to be involved in IL-18 production in macrophages and adipose tissue via increased
production of reactive oxygen species, which acts as a secondary signal for NLRP3 activation
leading to induction of caspase-1 cleavage and thereby increased IL-18 [62]. However, in the
current study IL-18 expression was decreased and not increased in skeletal muscle in HIV-
lipodystrophy, and ceramide can therefore not explain reduced expression of IL-18. In con-
trast, it is possible that low expression of IL-18 is causal involved in elevated content of cer-
amide, just like in the IL-18 deficient and IL-18 receptor deficient mice.
It is unknown whether increased level of ceramide is directly a cause of HAART, as no stud-
ies have demonstrated an effect of HAART per se on ceramide. Instead, hiv proteins (gp120 og
TAT) can induces sphingolipids [63]. In our patients viral load was below the detection limits
for all patients therefore it is unlikely that the increased levels of ceramide in muscle may be
induced by hiv per se. Instead, ectopic lipid deposition is a part of the lipodystrophy syndrome
seen in HAART treated HIV patients, and therefore the increased ceramide levels may be indi-
rectly results of the antiretroviral therapy.
IL-18 and mitochondrial activity
As described in rodents, IL-18 increases fatty acid oxidation through activation of AMPK and
mitochondrial oxidation [21]. Patients with HIV-lipodystrophy display impaired fat oxidation
[30] [29] and two recent studies show impaired mitochondrial oxidative phosphorylation
[64,65] and activity of enzymes involved in fat oxidation; e.g. β-HAD and citrate synthase [33]
in skeletal muscle in HIV patients. Our data is in accordance with those findings as we found
reduced expression of β-HAD and cytochrome c oxidase mRNA in skeletal muscle in HIV
patients with lipodystrophy. Furthermore, we showed that the ceramide content is negatively
correlated with the expression of β-HAD. It has previously been demonstrated that ceramides
alter mitochondrial dynamics in skeletal muscle [41] and therefore, impaired mitochondrial
function may be secondary to increased ceramide observed in skeletal muscle in patients with
HIV-LD. However, impaired mitochondrial fatty acid oxidation is also known to increase
IMCLs, diacylglycerols, and ceramides [66].
As specific mRNA measurements correlated to each due to the use of the same house keep-
ing gene (GAPDH) it was not possible to make a correlational relationship analysis between
IL-18 mRNA expression and mRNA expression of mitochondrial gene in our study. As a nega-
tive correlation between ceramide content and the expression of β-HAD mRNA as well as a
negative correlation between ceramide content and the expression of IL-18 mRNA were
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present, we can only speculate that IL-18 mRNA may correlate to expression of mitochondrial
genes as well.
In conclusion, our findings suggest that muscular IL-18 may be involved in the regulation
of intramuscular lipid metabolism and hypertriglyceridemia.
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